By Ana Espino | Published on February 13, 2026 | 3 min read
Congenital heart defects (CHD) are the most common congenital
anomalies, affecting approximately 1% of all births. Thanks to
significant advances in surgery and medical care, survival rates have
greatly improved, transforming what was once a lethal condition into a
chronic one. However, this success has brought to light a long-overlooked
complication: neurodevelopmental disorders (NDD).
Current management remains primarily
focused on the anatomical and functional correction of the heart. Yet a significant
proportion of children who undergo surgery later develop cognitive,
motor, language, or behavioral difficulties, which are often not
detected early. The lack of systematic neurological follow-up,
limited integration of multidisciplinary care pathways, and absence of predictive
tools hinder effective prevention and support.
The key challenge now is to understand
the mechanisms linking cardiac defects to brain vulnerability, starting as
early as the prenatal period, in order to guide earlier screening and
targeted interventions. One of the most promising avenues is a detailed
analysis of heart-brain interactions, using neuroimaging, biomarkers, and
developmental trajectories.
In this context, the aim of this
review was to investigate the connections between CHD and neurodevelopmental
outcomes, by identifying key risk factors, critical periods, and potential
strategies for early, comprehensive, and personalized follow-up.
Could it all begin in utero ?
The primary methodological objective was
to identify early brain alterations associated with cardiac malformations,
and to link these with medium- and long-term neurocognitive outcomes.
The analysis also incorporates perioperative factors (such as
cardiopulmonary bypass, chronic hypoxia, and postoperative complications), as
well as environmental influences (socioeconomic status, family
stimulation), which are recognized as modulators of neurodevelopmental risk.
Findings reveal that children with
CHD—particularly those with complex cyanotic forms (e.g., hypoplastic
left heart syndrome)—present with:
- Detectable in utero brain abnormalities, especially in the white matter and
cortex;
- Reduced cerebral blood flow, impacting neuronal growth
and maturation;
- Persistent brain immaturity at birth, observable on MRI even after
surgical correction;
- A higher risk of neurodevelopmental disorders in childhood,
including lower IQ, attention deficits, dyspraxia,
and autism spectrum features.
Aggravating factors include longer
cardiopulmonary bypass durations, chronic hypoxia exposure, and surgical
complications. Conversely, early multidisciplinary care, structured
neurocognitive monitoring, and a stable, stimulating family environment
appear to be protective.
From heart monitoring… to brain
monitoring
Congenital heart disease is now a better-managed
chronic pediatric condition from a hemodynamic standpoint, but it still
carries a significant and underrecognized risk of long-term neurodevelopmental
complications. The current challenge lies in addressing neurological
risks early, starting at the prenatal diagnosis, to improve
cognitive, motor, and educational outcomes.
This review aimed to shed light on early
interactions between cardiac disease and brain development, and to identify
opportunities for prevention and targeted intervention. The evidence
confirms that brain vulnerability begins in fetal life, supporting the
need for routine neurological follow-up alongside cardiac surveillance.
However, limitations in this review
remain and call for further research. These include the need for large,
multicenter longitudinal studies, advanced neuroimaging investigations,
the identification of early biomarkers of brain vulnerability, and evaluation
of targeted intervention programs in both school and home environments. The
future of care lies in integrated pediatric cardiology, focused not only
on survival but on long-term neurological quality of life.
About the author – Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions through impactful communication.
